By Roshan Fernandez
Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9.
Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in Alzheimer's disease drug development. Kupiec has been chief medical officer since December 2022 following a stint as Cassava's chief clinical development officer. He previously worked at Pfizer.
Cassava on Monday also said it appointed Jack Moore as senior vice president of clinical development. Moore was most recently the head of global medical affairs at Alector, and also worked at Janssen Pharmaceutica, Novartis Pharmaceuticals, and Celgene.
Write to Roshan Fernandez at roshan.fernandez@wsj.com
(END) Dow Jones Newswires
April 21, 2025 17:17 ET (21:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。